Matching Swiss venture capital with Swedish life science companies

A selected group/platform of some of the most interesting Life Science investors in Switzerland and Europe with interest in Swedish Life Science companies: Novartis Venture Funds is one of the world’s largest corporate biotech venture funds managing MUSD 750. HBM Partners is among the global leaders in Life Science-focused investing with USD 1 billion under management. Red Alpine is active in early stage venture capital fund investing in Life Science and ICT with focus on e.g. Scandinavia. BBBiotechVentures is a healthcare dedicated venture capital fund in the Bellevue Group (listed on the SIX Swiss Exchange)
Access to key decision makers and dedicated feedback on your company
Opportunity to get short listed for in-depth discussions with venture capital funds

Drug development, biotech platforms, medtech/medical device, diagnostics, therapeutics
From start-up/seed capital to late stage investments. From R&D, clinical studies and human proof-of-concept trials to registration trials/marketing and businesses/growth capital
Investment range MEUR 0.1-30
Innovative and leading companies in their niche

Register no later than June 28th trough the attached form or online at www.swedishtrade.se/sv/calendarpage/matching-swiss-venture-capital-with-swedish-life-science-companies and you will be contacted by Invest Sweden or the Swedish Trade Council with further information.

Even in the current down turn Swiss VC investments in Life Science show steady volumes and actually increases relative other segments
The VCs see a problem in the low “deal flow” i.e. a lack of interesting business venture
The Swiss VCs invest 90% of their capital (that is to a relative high degree foreign capital) in European ventures. Historically, however investments in Swedish entities have not been substantial

An initiative by Invest Sweden and Swedish Trade Council in collaboration with Swedish Medtech, Swecare and Sweden Bio.